riluzole has been researched along with Parkinson Disease, Secondary in 13 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 5.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Riluzole is a neuroprotective drug used in the treatment of motor neurone disease." | 1.38 | Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012) |
| "Riluzole, has previously been shown to be protective in animal models of Parkinson's disease in vivo." | 1.31 | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. ( Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S, 2000) |
| "Cotreatment with riluzole (4 mg/kg i." | 1.30 | Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. ( Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F, 1997) |
| "Pretreatment with riluzole (8 mg kg-1, i." | 1.29 | Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo. ( Boireau, A; Doble, A; Dubédat, P; Meunier, M; Miquet, JM, 1994) |
| "Riluzole pretreatment induced a persistent increase in dopamine turnover when compared to MPTP alone." | 1.29 | Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. ( Benazzouz, A; Boireau, A; Boraud, T; Dubédat, P; Gross, C; Stutzmann, JM, 1995) |
| "Riluzole was administered twice 15 min before, and 24 h after, the lesion." | 1.29 | Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. ( Barnéoud, P; Boireau, A; Doble, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensimon, G | 1 |
| Ludolph, A | 1 |
| Agid, Y | 1 |
| Vidailhet, M | 1 |
| Payan, C | 1 |
| Leigh, PN | 1 |
| Carbone, M | 1 |
| Duty, S | 1 |
| Rattray, M | 1 |
| Gilgun-Sherki, Y | 1 |
| Melamed, E | 1 |
| Ziv, I | 1 |
| Offen, D | 1 |
| Boireau, A | 6 |
| Dubédat, P | 5 |
| Bordier, F | 2 |
| Peny, C | 1 |
| Miquet, JM | 3 |
| Durand, G | 1 |
| Meunier, M | 2 |
| Doble, A | 3 |
| Benazzouz, A | 1 |
| Boraud, T | 3 |
| Stutzmann, JM | 5 |
| Gross, C | 1 |
| Barnéoud, P | 1 |
| Mazadier, M | 1 |
| Parmentier, S | 1 |
| Palfi, S | 1 |
| Riche, D | 1 |
| Brouillet, E | 1 |
| Guyot, MC | 1 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Peschanski, M | 1 |
| Hantraye, P | 1 |
| Bezard, E | 2 |
| Imbert, C | 1 |
| Gross, CE | 2 |
| Bioulac, B | 1 |
| Imperato, A | 2 |
| Moussaoui, S | 2 |
| Hassani, OK | 1 |
| Mouroux, M | 1 |
| Bohme, GA | 1 |
| Féger, J | 1 |
| Obinu, MC | 1 |
| Reibaud, M | 1 |
| Blanchard, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy[NCT02422485] | Phase 1 | 10 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)[NCT00211224] | Phase 3 | 800 participants | Interventional | 2000-04-30 | Terminated | ||
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy[NCT02460731] | Phase 1 | 6 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies[NCT01056965] | Phase 1 | 12 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticoba[NCT02133846] | Phase 1 | 44 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for riluzole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
12 other studies available for riluzole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Excitatory Amino | 2012 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug | 2003 |
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 1994 |
Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Exc | 1994 |
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.
Topics: Animals; Antiparkinson Agents; Dopamine; Electromyography; Excitatory Amino Acid Antagonists; Macaca | 1995 |
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Brain Chemistry; Ce | 1996 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; | 1997 |
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Behavior, Animal; Disease Mo | 1998 |
Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Electr | 2000 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2000 |
Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.
Topics: Adrenergic Agents; Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Male; Models, | 2001 |
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models, | 2002 |